Melvin R. Goodes Prize for Excellence in Drug Development honors an innovative researcher who has made a significant and lasting impact in the field.

Drug development researchers in the Alzheimer's field are often under-recognized for the critical contributions they make toward developing effective treatments for this disease. The Goodes Prize recognizes their determined efforts. It is named for Melvin R. Goodes, a distinguished leader in the pharmaceutical industry, who brought about drug breakthroughs that improved millions of lives.

As a leader in supporting the most promising Alzheimer's drug development research worldwide, the ADDF is proud to present the Goodes Prize to those men and women who have dedicated their careers to finding a cure for this devastating disease. It includes $150,000 to support the winner's future research in Alzheimer's drug discovery.

Winners

2015: Frank Longo, MD, PhD

2016: D. Martin Watterson, PhD

2017: Roberta Diaz Brinton, PhD

2018: Michela Gallagher, PhD

2019: Jeffrey Cummings, MD

2020: Jerri M. Rook, PhD

2021: Miia Kivipelto, MD, PhD

2022: Miranda E. Orr, PhD

2023: Rhoda Au, PhD, MBA

2024: Henrik Zetterberg, MD, PhD

2025: Daniel M. Skovronsky, MD, PhD